How GLP-1s may complicate antidepressant response—and how to talk to patients about it
Industry Buzz
When we first introduced GLP-1s for aesthetic weight loss, I think everyone was focused on the GI side effects... But the mental health side effects are starting to become a lot more prominent.
—Preston Roche, MD
Eh. I take lexapro and after starting wegovy I finally had energy and focus again, and far less anxiety. It's not the same for everyone.
—Patient account via Instagram @noelbfisher
When patients start a GLP-1, they’re usually warned about nausea, constipation, delayed gastric emptying, and the rare risk of pancreatitis.
Increasingly, however, some clinicians say they’re hearing a different complaint: “I think my antidepressant stopped working. I don’t enjoy anything anymore.”
The observation has been making the rounds on social media, including in a recent Instagram Reel by psychiatry resident Preston Roche, MD, who says he’s heard patients report worsening anhedonia or emotional blunting after starting semaglutide.
“When we first introduced GLP-1s for aesthetic weight loss, I think everyone was focused on the GI side effects. … But the mental health side effects are starting to become a lot more prominent,” he says.
In some cases, he says, patients assume their SSRIs are no longer effective when the timing actually coincides with initiation of a GLP-1. The anecdotes raise an important clinical question: Can GLP-1 drugs alter the effectiveness of antidepressants?
The answer isn’t entirely clear yet. But researchers are beginning to investigate why some patients report emotional changes while others experience the opposite.
The brain—not just the stomach
Although GLP-1 drugs are best known for slowing gastric emptying and reducing appetite, GLP-1 receptors are distributed throughout the central nervous system.
Among the brain regions of interest is the nucleus accumbens, a major hub in the mesolimbic dopamine reward pathway.[] Activation of GLP-1 receptors in this circuit appears to reduce the pleasurable properties of food—a key mechanism behind decreased cravings and weight loss.[]
This effect may not be limited to food. Researchers have found that GLP-1 signaling can dampen dopamine release within reward circuits and reduce reward-seeking behaviors.[]
Is this why patients say their antidepressant stopped working?
It’s one possible explanation. Patients often describe the experience as emotional flattening rather than classic depression.
Some say they no longer feel excited about hobbies, relationships, sex, or social activities. Others report they simply “don't care” in a way that feels unfamiliar, Dr. Roche says.
Because SSRIs themselves can also produce emotional blunting, the combination can make it difficult to determine what’s actually driving symptoms.
Another complicating factor is timing. Many patients have been psychiatrically stable for years before beginning a GLP-1 medication. When emotional changes emerge within weeks or months afterward, it’s understandable that they conclude their antidepressant has lost effectiveness.
Whether the GLP-1 is directly responsible, or simply unmasks underlying symptoms, remains an open question.
Related: The GLP-1 dosing mistakes sending more patients to poison controlWhat does the evidence actually show?
The data are mixed. GLP-1 receptor agonists may actually improve depression symptoms in some patients, possibly through weight loss, better metabolic health, reduced inflammation, and improved quality of life.[]
On the other hand, reports have documented cases of depression, mood changes, and suicidal thoughts in patients taking GLP-1s.[]
Available data have not demonstrated a causal link between GLP-1s and these symptoms, but it’s recommended to monitor patients on GLP-1s who are experiencing them.[]
How to counsel patients
The key message is awareness rather than alarm.
When prescribing or inheriting a patient on both a GLP-1 and an SSRI, consider asking a few additional questions:
Have you noticed less enjoyment from activities you used to like?
Are you feeling emotionally flat or simply less interested in things?
Did these symptoms begin after starting or increasing the GLP-1?
Are your depression symptoms returning, or does this feel different?
Have you noticed changes in your stimulant or other psychiatric medications?
Patients often assume they’re imagining these changes. Simply asking about them can help distinguish medication effects from relapse of depression.
Related: 'Ozempic penis' could push patients toward risky peptide stacks